|
(ÁÖ)ÇÇÇÃÄɾî½áÄ¡ |
¢º ÀÇ·á±â±â ¿µ¾÷
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
05.06 |
|
|
(ÁÖ)ÇÇÇÃÄɾî½áÄ¡ |
¢º À¯ºñÄõÅͽº ÇコÄɾî(Healthcare) °ü·Ã »ç¾÷±âȹ ¹× ¿µ¾÷
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
1³â¡è |
ä¿ë½Ã |
05.06 |
|
|
(ÁÖ)ÇÇÇÃÄɾî½áÄ¡ |
¢º RA(Regulatory Affairs), ÀÇ·á±â±â ÇØ¿Ü ÀÎÇã°¡( RA)¾÷¹«
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.14 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Commercial Process Excellence Manager/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿µ¾÷°ü¸®/¿µ¾÷Áö¿ø |
10³â¡è |
ä¿ë½Ã |
03.11 |
|
|
ÁÖ½Äȸ»ç ÀÎÅÚ¸®Àü½ºÄÚ¸®¾Æ |
¿Ü±¹°èÁ¦¾àȸ»ç / ±³À°°£È£»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°£È£»ç |
2³â¡è |
ä¿ë½Ã |
06.10 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Market Access(¾à°¡´ã´çÀÚ)/±¹³»majorÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
12.03 |
|
|
ÁÖ½Äȸ»ç ÀÎÅÚ¸®Àü½ºÄÚ¸®¾Æ |
¿Ü±¹°è Á¦¾à»ç µµ¸Å¿µ¾÷
¼¿ï °³²±¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
05.06 |
|
|
JYpartners |
[[¾à»ç, ÇѾà»ç Çʼö]] CRA 2³â ÀÌ»ó °æ·ÂÀÚ OK
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
05.06 |
|
|
JYpartners |
Local CRO±â°ü CRA/CRM/Dedicated CRA ±¸ÀÎ
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
»ó½Ãä¿ë |
05.06 |
|
|
JYpartners |
[[±Þ±¸]] PV or CRA 2³â ÀÌ»ó °æ·ÂÀÚ PV manager
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
03.11 |
|
|
(ÁÖ)¸®¿ÂÆÄÆ®³Ê½º |
±Û·Î¹ú/·ÎÄà Á¦¾à»ç ÀÓ»óÀü·«/CTM/Pricing/BD/PM/QA/¿¬±¸°³
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
05.06 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
¼÷ÃëÀ½·áJPM/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
09.21 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
MSL(CNSÁ¦Ç°)/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
3³â¡è |
ä¿ë½Ã |
12.12 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Oncology Brand Manager(Æó¾Ï½ÅÁ¦Ç°)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
12.12 |
|
|
(ÁÖ)ÄھƼġ |
ÇصåÇåÅÍ,¸®¼Ã³
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
08.05 |
|